Published in Surgery Litigation and Law Weekly, November 24th, 2006
This trend article about University of Texas, U.S., is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Combination antifungal therapy may be most valuable in the pre-emptive management of carefully selected high-risk immunocompromised patients.
According to a recent review published in the journal Current Opinion in Infectious Diseases, "Despite expansion of the antifungal armamentarium over the past decade, the mortality rate for invasive fungal infections remains high in severely immunocompromised patients.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.